Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Merck (MRK) stock in plain English

Free brief · no signupStart here
MRKPublished Nov 7, 2026
Merck & Co Inc
Healthcare · Drug Manufacturers - General
Sells prescription oncology drugs, human vaccines, hospital acute care therapies, and livestock medications worldwide.
Assets:
Keytruda oncology assetGenerates over forty percent of total corporate revenue
Global vaccine portfolioProduces Gardasil for human papillomavirus and pediatric vaccines
Animal Health unitSupplies livestock and companion animal pharmaceuticals and vaccines
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

32
OPS ScoreOperating finances
Latest quote
-3.61%$132.81
$327.41B
135.6×
$67.23B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 07, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was MRK. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Merck (MRK) do?

Merck & Co Inc (MRK) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Sells prescription oncology drugs, human vaccines, hospital acute care therapies, and livestock medications worldwide. Manufactures prescription medicines, vaccines, and animal health products, relying heavily on a blockbuster oncology. It is worth $327.41B on the market and sold $67.23B over the last year.

Market cap
$327.41B
P/E ratio
135.6×
Annual sales
$67.23B
Sector
Healthcare
Industry
Drug Manufacturers - General
Brief updated
Nov 07, 2026

Brands and businesses behind MRK

  • Keytruda: Immunotherapy drug treating various cancers, sold globally to hospitals and cancer clinics.
  • Gardasil: Vaccine protecting against human papillomavirus, sold to healthcare providers, public clinics, and governments.
  • Januvia: Oral medication for type 2 diabetes, generating revenue via retail pharmacies and prescription drug plans.
  • Bridion: Reversal medication for anesthesia muscle relaxants, generating sales from hospital surgical departments worldwide.
  • Bravecto: Veterinary medication protecting companion animals from fleas and ticks, sold through veterinary clinics and distributors.

MRK’s flags, in plain English

Each flag is a number from Merck’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 07, 2026.

Wide Gross Margin

Gross margin of 69.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 9.3% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Pays You to Hold

Pays a 2.56% dividend a year. The company pays part of its profit to shareholders in cash. A dividend can be cut, so it is not guaranteed.

Debt Is Driving

Heavy debt, 120% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

1 more risk note open with the free trial. Try it free for 7 days.

Questions about MRK

How big is Merck?

Merck’s market cap is $327.41B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $67.23B: what customers paid the company over the last year, before any costs.

What is MRK’s P/E ratio?

MRK’s P/E ratio is 135.6×. Investors pay about 135.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with MRK?

Keytruda accounts for nearly half of company revenue, creating high vulnerability to its upcoming patent expiration. That is one risk on Merck’s card. Its first risk flag is Debt Is Driving, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Merck’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. MRK’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card